Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Primary Immunodeficiency (PID) Clinical Trial

Official title:
A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push.

Status Completed

Clinical Trial Summary

The purpose of this study is to compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL according to the delivery device.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02180763
Study type	Interventional
Source	Octapharma
Contact
Status	Completed
Phase	Phase 4
Start date	April 2014
Completion date	August 26, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01287689` - Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study	N/A
Recruiting	`NCT01962415` - Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT	Phase 2
Completed	`NCT00751621` - Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)	Phase 3
Recruiting	`NCT04528355` - Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Completed	`NCT00391131` - Subcutaneous Ig NextGen 16% in PID Patients	Phase 3